Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

In addition to each of the factors that govern the identification of a successful oncology drug
candidate, drug discovery aimed at treating neurological cancer must also consider the …

Smoking tobacco, both cigarettes and beedis, is the principal risk factor for causation of lung
cancer in Indian men; however, among Indian women, the association with smoking is not …

Brain metastasis (BM) is associated with poor prognosis in patients with non-small cell lung
cancer (NSCLC). We sought to identify microRNAs (miRNAs) that could serve as biomarkers …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Background/Aims We investigated the time taken for patients with metastatic non-small cell
lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall …

Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …

This study compared treatment outcomes between TKI monotherapy and TKI administration
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …

The aim of the present study was to analyze the impact of metastatic status on the prognosis
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …

Lung cancer is a leading cause of death globally. It is also a major healthcare problem in
India.[1] An online search using the words “lung cancer India” yielded the following hits on …